Rapid resistance profiling of SARS-CoV-2 protease inhibitors.

Reuben Stewart HarrisSeyed MoghadasiRayhan G Biswas Daniel A Harki

Published in: Research square (2023)

Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (Mpro) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001. The results reveal distinct resistance mechanisms ("fingerprints") and indicate that these next-generation drugs have the potential to be effective against nirmatrelvir-resistant variants and vice versa.

Keyphrases

sars cov
respiratory syndrome coronavirus
single cell
copy number
gene expression
high throughput
stem cells
climate change
genome wide
mesenchymal stem cells